Here is the press release:
"Safety and Antiviral Activity of ANA598 in Combination with Pegylated Interferon alpha-2A Plus Ribavirin in Treatment-Naive Genotype 1 Chronic HCV Patients"; April 15, 2010.
Anadys will present preliminary antiviral response and safety results from its ongoing Phase II study of ANA598 in HCV patients, in which ANA598 is being dosed for 12 weeks in combination with pegylated interferon and ribavirin (SOC). For the group receiving ANA598 at 400 mg twice-daily (bid) plus SOC, antiviral response and safety data through eight weeks will be presented, which data further confirm the profile demonstrated for ANA598 at 200 mg bid. Antiviral response and safety data for the complete control group receiving placebo plus SOC will also be updated through eight weeks. Data through 12 weeks will be presented for the group that received ANA598 200 mg bid plus SOC.
Poster Presentation on ANA598 Preclinical Data:
"Enhanced In Vitro Antiviral Activity of ANA598 in Combination with Other Anti-HCV Agents Support Combination Treatment"; April 16, 2010.
Anadys will present preclinical data showing enhanced activity and suppression of resistance when ANA598 is combined in vitro with other anti-HCV agents.
The abstracts for both presentations can be accessed through the EASL website at www.easl.ch. Thanks Yahoo finance.
More on this later tonight after I do some reading.
No comments:
Post a Comment